Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience Maria Teresa Congedo, MD, Alfredo Cesario,

Slides:

Advertisements

Similar presentations

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Advertisements

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection Giovanni Leuzzi, MD,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Malignant Solitary Fibrous Tumors of the Pleura: Retrospective Review of a Multicenter Series Filippo Lococo, MD, Alfredo Cesario, MD, Giuseppe Cardillo,

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Pleomorphic carcinoma of the lung: A surgical outcome

Lung hernia after en bloc cervicothoracic resection

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent.

Intrinsic cardiac stem cells are essential for regeneration

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The lord of the rings Antonio Miceli, MD, PhD

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Small-bore wire-guided chest drains: Safety, tolerability, and effectiveness in pneumothorax, malignant effusions, and pleural empyema Stefano Cafarotti,

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

A first start for lung transplantation?

Is surgery for multiple lung metastases reasonable

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response.

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Historical perspectives of The American Association for Thoracic Surgery: Robert M. Janes, MD ( ) Myunghyun Lee, MD, Vivek Rao, MD, PhD The.

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Multifocal lung cancer within ground glass lesions: Are favorable outcomes consequent to surgical resection or inherent to the disease? Mara B. Antonoff,

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Who should decide margin length in pulmonary excision of lung cancer?

The clinical stage of non–small cell lung cancer as assessed by means of fluorodeoxyglucose–positron emission tomographic/computed tomographic scanning.

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

Induction Therapy Followed by Surgery for T3-T4/N0 Non-Small Cell Lung Cancer: Long-Term Results Filippo Lococo, MD, Alfredo Cesario, MD, Stefano Margaritora,

Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non–small cell carcinoma Akira Iyoda, MD, Kenzo.

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience Maria Teresa Congedo, MD, Alfredo Cesario, MD, Filippo Lococo, MD, Chiara De Waure, MD, Giovanni Apolone, PhD, Elisa Meacci, MD, Sergio Cavuto, MD, Pierluigi Granone, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 144, Issue 2, Pages 444-452 (August 2012) DOI: 10.1016/j.jtcvs.2012.05.051 Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Survival: Overall survival of the entire cohort of patients (A), local disease-free survival (L-DFS) (B), and distant disease-free survival (D-DFS) (C). LTS, Long-term survival. The Journal of Thoracic and Cardiovascular Surgery 2012 144, 444-452DOI: (10.1016/j.jtcvs.2012.05.051) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Long-term survival (LTS) (A) and local disease-free survival (L-DFS) (B) according with the completeness of resection. Long-term survival (C) and distant disease-free survival (D-DFS) (D) according to the presence of a weight loss (>10% in the last 6 months before treatment). The Journal of Thoracic and Cardiovascular Surgery 2012 144, 444-452DOI: (10.1016/j.jtcvs.2012.05.051) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Prognostic factors after multimodal treatment for oligometastatic; pathologic N status (A) and adjuvant therapy (B) are related to local disease-free survival (L-DFS) whereas the choice of surgical resection of the distant metastases (C) and the execution of whole brain radiation (D) seem to significantly influence the distant disease-free survival (D-DFS). The Journal of Thoracic and Cardiovascular Surgery 2012 144, 444-452DOI: (10.1016/j.jtcvs.2012.05.051) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 The prognostic role of fluorodeoxyglucose positron emission tomographic–computed tomographic (PET–CT) scan: impact on long-term survival (LTS) (A) and distant disease-free survival (D-DFS) (B). The Journal of Thoracic and Cardiovascular Surgery 2012 144, 444-452DOI: (10.1016/j.jtcvs.2012.05.051) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions